ABSTRACT

Background

Chronic heart failure (CHF) is a clinical status and a progressive health disorder extremely related to increased morbidity and mortality worldwide. Accordingly, this study aimed to assess systematic review of literature on cost-effectiveness done in patients with heart failure receiving Ivabradine plus standard treatment compared with standard treatment alone.

Areas covered

This study is a systematic review in which all published articles related to the study topic were assessed in time range of 2014–2020. In order to find articles, internet search in foreign databases of PubMed, Embase, ISI/Web of Science (WoS), SCOPUS, Global Health databases, through keywords related to the objective was performed. Six articles out of 1524 article related to final topic were assessed. In addition, quality of studies was evaluated using CHEERS checklist. In six countries investigated (Iran, Thailand, Australia, United States of America, United Kingdom, and Greece), willingness-to-pay (WTP) thresholds higher cost per QALY, and highest ICER for Ivabradine was in USA (55,600 $/QALY) and the lowest was in Thailand (10,616$/QALY). Most items of CHEERS were estimated in the studies and studies had good quality.

Expert opinion

Regarding our investigation, ivabradine combined with standard care was more cost-effective than standard care alone in most of the evaluated studies, although the cost of this intervention was higher than its effectiveness. However, the threshold chosen by each country can have a significant impact on these results. And to have a more accurate result, it is required to pay more attention to the income level in different countries.

中文翻译：

---

伊伐布雷定治疗心力衰竭患者的经济评价：系统评价

摘要

背景

慢性心力衰竭 (CHF) 是一种临床状态，是一种进行性健康疾病，与全球发病率和死亡率的增加密切相关。因此，本研究旨在评估对接受伊伐布雷定联合标准治疗的心力衰竭患者与单独标准治疗相比的成本效益的文献系统评价。

涵盖的领域

本研究是一项系统评价，其中与研究主题相关的所有已发表文章均在 2014-2020 年的时间范围内进行了评估。为了找到文章，通过与目标相关的关键字在 PubMed、Embase、ISI/Web of Science (WoS)、SCOPUS、全球健康数据库的国外数据库中进行互联网搜索。评估了与最终主题相关的 1524 篇文章中的 6 篇。此外，使用 CHEERS 检查表评估研究质量。在被调查的六个国家（伊朗、泰国、澳大利亚、美国、英国和希腊）中，支付意愿 (WTP) 门槛较高的每 QALY 成本，伊伐布雷定的 ICER 最高的是美国（55,600 美元/QALY )，最低的是泰国 (10,616 美元/QALY)。研究中估计了大多数 CHEERS 项目，研究质量良好。

专家意见

关于我们的调查，在大多数评估的研究中，伊伐布雷定联合标准治疗比单独标准治疗更具成本效益，尽管这种干预的成本高于其有效性。但是，每个国家/地区选择的阈值可能会对这些结果产生重大影响。而要得到更准确的结果，就需要更加关注不同国家的收入水平。